8-K: TOMI Environmental Solutions Reports Strong Q2 Revenue Growth

TOMI Environmental Solutions announced a 118% year-over-year revenue increase for Q2 2026, reaching $2.25 million, and reaffirmed its full-year revenue guidance.

Summary

• TOMI Environmental Solutions reported a significant 118% year-over-year increase in second-quarter 2026 revenue, reaching $2.25 million, with a 36% sequential increase from the previous quarter.
• Gross profit more than doubled to $1.39 million, and gross margin improved to 61.7% from 50.3% in Q1 2026.
• The company reaffirmed its full-year 2026 revenue guidance of at least $12.0 million, representing an expected 113% year-over-year growth.
• Key strategic developments include signing a definitive merger agreement with Carbonium Core, Inc., securing unconditional EPA registration for SteraMist (BIT) AgriMist, and expanding European regulatory footprint to 11 countries.
• Operating loss for Q2 2026 improved by 78% to $(244,142), and net loss improved by 69% to $(382,299) compared to the prior year's quarter.
• Cash and cash equivalents increased to $321,899 as of June 30, 2026, up from $87,775 at the end of 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, driven by significant revenue growth, improved margins, and strategic advancements, despite an ongoing net loss.

Positives

• Q2 2026 revenue surged 118% year-over-year to $2.25 million, with a 36% sequential increase over Q1 2026.
• Gross profit more than doubled to $1.39 million, and gross margin improved to 61.7% from 50.3% in Q1 2026.
• Full-year 2026 revenue guidance of at least $12.0 million was reaffirmed, indicating strong expected growth.
• Secured unconditional EPA registration for SteraMist (BIT) AgriMist, expanding its application in agriculture.
• Expanded European regulatory footprint to 11 countries.
• Operating loss significantly improved by 78% to $(244,142) in Q2 2026.
• Net loss improved by 69% to $(382,299) in Q2 2026.
• Cash and cash equivalents increased substantially to $321,899 from $87,775 at year-end 2025.

Negatives

• The company reported a net loss of $(382,299) for the second quarter of 2026.
• Despite improvements, the company is still operating at a loss from operations of $(244,142) for the quarter.
• The company's cash and cash equivalents remain relatively low at $321,899 as of June 30, 2026.

Risks

• The proposed merger with Carbonium Core, Inc. is subject to customary closing conditions, including completion of contemplated financing activities, regulatory and other approvals, and continued compliance with Nasdaq requirements.
• There can be no assurance that the merger transaction will be completed on the anticipated terms, within the expected timeframe, or at all.
• Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially, including risks related to the completion of the merger, the ability of the combined company to execute its strategy, and the commercialization of Carbonium's technology.
• Reliance on a limited number of products for a significant portion of revenues.
• Risks described in TOMI's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Future Outlook

The company reaffirms its full-year 2026 revenue guidance of at least $12.0 million. TOMI expects to complete the merger with Carbonium Core, Inc., drive recurring revenue growth, convert its commercial pipeline and backlog, advance high-value technical and regulatory pathways, and expand defense and institutional sales.

Management Comments

• "The second quarter of 2026 was a defining operational and commercial period for TOMI, delivering our third consecutive quarter of accelerating growth, with year-over-year revenue growth of 118% to $2,247,000."
• "Gross profit roughly doubled, and with strict cost control, the Company continues to work toward operating at breakeven on a cash basis."
• "We believe this performance reflects strong execution across our razor-and-blade commercial model, driven by surge demand for capital equipment, Custom Engineered Systems, and rapid adoption of our SteraMist applicators."
• "We made critical advances across our technical, regulatory, and commercial pipelines."
• "We are excited for the future of TOMI and look forward to providing additional updates in the near term."

Industry Context

StockSavvy.ai notes that TOMI's strong revenue growth in disinfection and decontamination aligns with increased global focus on public health and biosecurity. The expansion into agricultural applications with the AgriMist label and the strategic merger with Carbonium Core, Inc. (nuclear-grade graphite) suggest a diversification strategy into critical materials and advanced technologies.

Stakeholder Impact

• Shareholders: Potential positive impact from strong revenue growth and strategic merger, but ongoing net loss and merger completion risks remain.
• Employees: Continued investment in business development may lead to growth opportunities.
• Customers: Expanded product registrations (EPA AgriMist) and regulatory approvals (EU) offer broader application and availability of solutions.
• Suppliers: Increased demand for capital equipment and consumables may benefit suppliers.

Next Steps

• Complete the required $10 million concurrent financing and advance toward closing the definitive merger with Carbonium Core, Inc.
• Accelerate year-over-year recurring revenue through increased BIT Solution sales and applicator adoption.
• Convert key opportunities within the $35 million commercial sales pipeline and $2.5 million sales backlog.
• Progress the FDA 510(k) medical device clearance submission.
• Capitalize on the new EPA AgriMist label expansion in agricultural and food safety markets.
• Leverage 11 EU/UK regulatory authorizations to capture European cleanroom and life sciences demand.
• Scale distribution channels across defense and public health sectors.

Key Dates

Recommendation

The strong revenue growth and strategic progress are positive indicators. However, the company is still operating at a net loss, and the successful completion of the merger and its associated financing are critical. The current valuation and path to profitability warrant a cautious 'hold' stance pending further developments.

Keywords

Disinfection, Decontamination, Binary Ionization Technology, SteraMist, EPA Registration, Merger Agreement, Revenue Growth, AgriMist